Amneal Pharmaceuticals, Inc.
AMRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $785 | $725 | $695 | $731 |
| % Growth | 8.3% | 4.2% | -4.8% | – |
| Cost of Goods Sold | $511 | $438 | $440 | $468 |
| Gross Profit | $274 | $286 | $256 | $263 |
| % Margin | 34.9% | 39.5% | 36.8% | 36% |
| R&D Expenses | $63 | $50 | $42 | $56 |
| G&A Expenses | $0 | $0 | $0 | $94 |
| SG&A Expenses | $138 | $124 | $118 | $129 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $34 |
| Other Operating Expenses | $73 | $1 | -$5 | $2 |
| Operating Expenses | $274 | $175 | $156 | $187 |
| Operating Income | -$0 | $111 | $100 | $76 |
| % Margin | -0% | 15.4% | 14.4% | 10.4% |
| Other Income/Exp. Net | -$5 | -$60 | -$63 | -$91 |
| Pre-Tax Income | -$5 | $52 | $37 | -$15 |
| Tax Expense | -$23 | $16 | $13 | $5 |
| Net Income | $2 | $22 | $12 | -$31 |
| % Margin | 0.3% | 3.1% | 1.8% | -4.3% |
| EPS | 0.008 | 0.071 | 0.039 | -0.1 |
| % Growth | -89.5% | 82.1% | 139.2% | – |
| EPS Diluted | 0.008 | 0.07 | 0.038 | -0.1 |
| Weighted Avg Shares Out | 314 | 314 | 311 | 310 |
| Weighted Avg Shares Out Dil | 325 | 322 | 324 | 310 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $63 | $65 | $57 | $62 |
| Depreciation & Amortization | $54 | $60 | $60 | $66 |
| EBITDA | $112 | $177 | $155 | $112 |
| % Margin | 14.2% | 24.4% | 22.2% | 15.4% |